# Patient Care Plan

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Frederick Law Olmsted (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI022-SYN
- Date: 2026-05-05
- Fictional facility: St. Posthumous Health Center
- Fictional author: Nathan Calder, MD
- Calendar frame: modern shifted

## What we are working on

- He is frustrated that he can no longer keep the details of his projects in mind and wants to understand what is happening **S**
- His caregiver wants to keep him safe at home and needs help and information **S**

## Your goals

- Complete the reversible-cause tests and brain MRI and discuss the diagnosis with him and his caregiver by the four-week visit. Target: 2026-06-02. Recorded outcome: Tests and MRI showed no reversible cause; diagnosis of mild dementia of undetermined type discussed with both. **S**
- A safety plan in place by the three-month review: no driving, medicines supervised, finances overseen, and medical identification worn. Target: 2026-08-04. Recorded outcome: Stopped driving after the consultation; caregiver gives medicines from a weekly organizer and oversees bill paying with his agreement; medical identification bracelet worn. **S**
- Donepezil at 10 mg daily without side effects and with resting heart rate 55 or above by the six-month review. Target: 2026-10-27. Recorded outcome: On 10 mg for three months; heart rate 60; no nausea, diarrhea, weight loss, or vivid dreams. **S**
- Caregiver burden assessed and support in place by the six-month review. Target: 2026-10-27. Recorded outcome: Zarit Burden Interview 24 at three months; caregiver education program completed and two days a week of adult day program begun. **S**
- Name a health care agent and record his values and wishes while he can take full part, by the three-month review. Target: 2026-08-04. Recorded outcome: Health care agent named and his wishes recorded at the three-month review. **S**

## What we agreed to do

- Reversible-cause tests (blood count, metabolic panel, vitamin B12, folate, TSH) and one non-contrast brain MRI; syphilis and HIV testing only with risk factors or atypical features. Guideline: Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology (2001); Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): Executive summary of recommendations for primary care (2025); CMID: Clinical Monitoring Intelligence Database, Non-Alzheimer's dementia and Alzheimer's disease monographs (2026) **S**
- Behavioral neurology consultation to confirm the diagnosis, consider the type and biomarker testing, and advise on treatment and driving. Guideline: Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology (2001); Practice parameter update: evaluation and management of driving risk in dementia: report of the Quality Standards Subcommittee of the American Academy of Neurology (2010); The Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): Executive summary of recommendations for specialty care (2025) **S**
- Donepezil trial, 5 mg daily for four to eight weeks then 10 mg, with heart rate, fainting, gastrointestinal effects, weight, and sleep checked at each visit; avoid anticholinergic drugs, first-generation antihistamines, benzodiazepines, and sleeping pills (AGS Beers Criteria). Guideline: American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults (2023); CMID: Clinical Monitoring Intelligence Database, Non-Alzheimer's dementia and Alzheimer's disease monographs (2026) **S**
- Safety: stop driving at CDR 1, keep the home free of firearms, medical identification for wandering, supervised medicines and finances, and home safety. Guideline: Practice parameter update: evaluation and management of driving risk in dementia: report of the Quality Standards Subcommittee of the American Academy of Neurology (2010); CMID: Clinical Monitoring Intelligence Database, Non-Alzheimer's dementia and Alzheimer's disease monographs (2026) **S**
- Caregiver support: Zarit Burden Interview at diagnosis and every six to twelve months, education, adult day program and respite, and Alzheimer's Association support services. Guideline: Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): Executive summary of recommendations for primary care (2025); CMID: Clinical Monitoring Intelligence Database, Non-Alzheimer's dementia and Alzheimer's disease monographs (2026) **S**
- Monitor on the CMID dementia schedule: medication review and neuropsychiatric screen at every visit; MoCA, ADL and IADL, CDR or FAST stage, depression screen, fall risk, driving, and advance care planning yearly; repeat tests or imaging only with a sudden change. Guideline: CMID: Clinical Monitoring Intelligence Database, Non-Alzheimer's dementia and Alzheimer's disease monographs (2026) **S**
- Advance care planning while he can take part: name a health care agent and record his values and wishes. Guideline: Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): Executive summary of recommendations for primary care (2025); CMID: Clinical Monitoring Intelligence Database, Non-Alzheimer's dementia and Alzheimer's disease monographs (2026) **S**

## Follow-up

- 2026-05-05: Cognitive evaluation for progressive memory loss: history from patient and caregiver, MoCA, function, mood, safety, and reversible-cause tests **S**
- 2026-06-02: Four-week follow-up: results and MRI review, diagnosis disclosure, and behavioral neurology consultation **S**
- 2026-08-04: Three-month dementia review: donepezil, safety plan, caregiver burden, and advance care planning **S**
- 2026-09-15: Subsequent annual wellness visit **S**
- 2026-10-27: Six-month dementia review **S**

This teaching document does not replace care from a qualified clinician.
